Table 7.
Results from the logit analysis of new hepatitis C drug use by HIV coinfection among LIS (low-income subsidy) enrollees
| Variable | Patients with HCV/HIV coinfection (N = 10,169) Odds ratio (95% CI) |
Patients with HCV infection only (N = 91,505) Odds ratio (95% CI) |
|---|---|---|
| Race (ref: non-Hispanic white) | ||
| Black | 0.80 (0.71–0.92)*** | 0.99 (0.93–1.04) |
| Hispanic | 1.01 (0.86–1.18) | 1.00 (0.94–1.07) |
| Cirrhosis | 2.37 (2.11–2.66)*** | 2.37 (2.26–2.49)*** |
| Age | 1.01 (1.00–1.02)*** | 1.00 (1.00–1.00)* |
| Male | 1.13 (1.01–1.27)** | 0.92 (0.88–0.97)*** |
| Number of chronic conditions | 0.85 (0.81–0.90)*** | 0.87 (0.86–0.88)*** |
| Having diabetes | 1.36 (1.18–1.56)*** | 1.14 (1.09–1.19)*** |
| Having hypertension | 0.99 (0.85–1.15) | 0.97 (0.93–1.02) |
| Having ischemic heart disease | 1.22 (1.03–1.45)** | 0.96 (0.91–1.00)* |
| Having hyperlipidemia | 1.21 (1.04–1.40)** | 1.01 (0.96–1.06) |
| Having depression | 1.01 (0.89–1.15) | 1.02 (0.98–1.07) |
| Having congestive heart failure | 0.63 (0.51–0.76)*** | 0.71 (0.66–0.76)*** |
| Having cataract | 1.40 (1.18–1.67)*** | 1.28 (1.20–1.35)*** |
| Having chronic obstructive pulmonary disease | 0.78 (0.66–0.93)*** | 0.82 (0.78–0.86)*** |
| Below median household income | 0.97 (0.86–1.09) | 0.86 (0.82–0.91)*** |
| Percent college educated | 1.00 (0.99–1.00) | 1.00 (1.00–1.00)* |
| Urban area | 1.37 (1.07–1.76)** | 1.01 (0.95–1.08) |
| Applying prior authorization | 1.29 (0.16–10.81) | 1.15 (0.65–2.04) |
| Enhanced plan | 1.09 (0.84–1.41) | 1.22 (1.12–1.33)*** |
| Gap coverage plan | 0.95 (0.63–1.43) | 0.92 (0.79–1.08) |
| Deduct | 0.86 (0.67–1.09) | 1.10 (1.03–1.17)*** |
| Region (ref: Northeast) | ||
| Midwest | 1.04 (0.85–1.27) | 1.03 (0.94–1.12) |
| South | 0.77 (0.64–0.93)*** | 0.92 (0.85–0.99)** |
| West | 0.80 (0.63–1.01)** | 0.76 (0.70–0.82)*** |
| Pseudo R2 | 0.0547 | 0.0553 |
| Log pseudolikelihood | −4101.8783 | −36,392.668 |
**
p < 0.01,
**
p < 0.05, and
*
p < 0.10; standard errors are clustered within a plan